Researchers from IBEC, in collaboration with an international team, describe the first molecules capable of regulate glycine receptors with light: Glyght and Azo-NZ1. The new molecules are a promising...
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that ...
According to a study published on January 9 in the journal Science Advances, led by the National University of Singapore, co-authored by Gustavo Deco, ICREA research professor and director of the Cent...
The new study gathers data on millions of common genetic variants in more than 800,000 people ─among patients and healthy volunteers─ which could be risk factors in 25 neurological and psychiatric...
“Bench-to-bedside” describes research that has progressed from basic science in animal models that has led to therapies used in patients. Now, a study in the journal Brain describes what could be ...